Sale

Human Insulin Market

Global Human Insulin Market Price, Share, Growth, Analysis, Forecast: By Product: Drugs, Delivery Device; By Type: Biosimilars, Delivery Device; By Brand: HI Analogs and Biosimilars, HI Biologics; By Delivery Device: Pens, Syringes, Pen Needles, Others; By Application; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Global Human Insulin Market Outlook

The global human insulin market value was USD 20.89 billion in 2023, driven by the rising prevalence of diabetes across the globe. The global human insulin market share is anticipated to grow at a CAGR of 3.4% during the forecast period of 2024-2032 to achieve a value of USD 28.22 billion by 2032.

 

Global Human Insulin Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Rising Incidence of Diabetes in North America to Aid the Market Growth of Human Insulin

The market for human insulin is expected to be driven by the growing demand from the North America region over the forecast period. This could be attributed to the rising incidence of diabetes and the increasing geriatric population, which are majorly contributing to the rising demand for human insulin in the region. On the basis of revenue, many countries in Europe like Germany, France, and Italy are predicted to contribute considerably to the growth of the human insulin industry over the forecast period. Meanwhile, the Asia Pacific region is expected to be a favourable market for human insulin over the forecast period. This could be ascribed to the growing research and development activities undertaken by various organisations and rising government initiatives in the region.

 

Human Insulin: Market Segmentation

Human insulin is referred to the synthetic insulin, which is grown in the laboratory and simulates the insulin in humans. The function of insulin is to regulate fat and carbohydrate metabolism in the body. It was developed through the 1960s and 1970s and finally approved for pharmaceutical use in 1982.

 

Global Human Insulin Market By Delivery Service

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

On the basis of product type, the market is divided into:

  • Drugs
  • Delivery Device

Based on type, the industry can be segmented into:

  • Insulin Analogs and Biosimilars
  • Delivery Device

Insulin analogs and biosimilars is further divided on the basis of types into long acting, rapid acting, and pre-mixed, whereas delivery device is divided into intermediate-acting, short-acting, pre-mixed.

By brand, the industry is categorised into:

  • NovoRapid/Novolog
  • Humalog
  • Insuman
  • Humulin
  • Lantus
  • Actrapid, Insulatard, and Mixtard
  • Others

On the basis of delivery service, the industry is segregated into:

  • Pens
  • Syringes
  • Pen Needles
  • Others

Based on applications, the industry is divided into:

  • Type 1
  • Type 2

The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

Global Human Insulin Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Rising Investments in R&D Activities to Aid the Market Growth of Human Insulin

The market for human insulin is driven by the rising cases of diabetes and obesity across the globe, which are the resultants of changing lifestyles and unhealthy consumption of sugar in various food and beverages. In addition, the rising investments in research and development activities by several organisations have led to an advanced and easier way of injecting insulin, which is also boosting the market growth of human insulin. Moreover, the introduction of the safety pen devices and pen needles for effective delivery of insulin is propelling the global market forward. Further, growing awareness of diabetes is expected to bolster the demand in the human insulin industry.

 

Key Industry Players in the Global Human Insulin Market

The report gives a detailed analysis of the following key players in the global human insulin market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • Novo Nordisk A/S
  • Biocon Limited
  • Sanofi S.A.
  • Pfizer Inc.
  • Eli Lilly and Company
  • Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Product
  • Type
  • Brand
  • Delivery Device
  • Application
  • Distribution Channel
  • Region
Breakup by Product
  • Drugs
  • Delivery Device
Breakup by Type
  • Biosimilars
  • Delivery Device
Breakup by Brand
  • HI Analogs and Biosimilars
  • HI Biologics
Breakup by Delivery Device
  • Pens
  • Syringes
  • Pen Needles
  • Others
Breakup by Application
  • Type I Diabetes
  • Type II Diabetes
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Nova Nordisk A/S
  • Biocon Limited
  • Sanofi S.A.
  • Pfizer Inc.
  • Eli Lilly and Company
  • Boehringer Ingelheim International GmbH
  • Tonghua Dongbao Pharmaceutical Co. Ltd.
  • Wockhardt
  • Julphar (Gulf Pharmaceutical Industries)
  • The United Laboratories International Holdings Limited
  • Ypsomed AG
  • Biodel Inc.
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Diabetes Overview

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Diabetes Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Diabetes Epidemiology (2016-2031)
    5.3    Europe Diabetes Epidemiology (2016-2031)
    5.4    Asia-Pacific Diabetes Epidemiology (2016-2031)
    5.5    Latin America Diabetes Epidemiology (2016-2031)
    5.6    Middle East & Africa Diabetes Epidemiology (2016-2031)
6    Global Human Insulin Market Overview 
    6.1    Global Human Insulin Market Historical Value (2017-2023) 
    6.2    Global Human Insulin Market Forecast Value (2024-2032)
7    Global Human Insulin Market Landscape
    7.1    Global Human Insulin Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Global Human Insulin Product Landscape
        7.2.1    Analysis by Product Type
        7.2.2    Analysis by Distribution Channel
        7.2.3    Analysis by Applications
8    Human Insulin Market Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Global Human Insulin Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model 
    10.4    Key Demand Indicators
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends 
    10.7    Value Chain Analysis
11    Global Human Insulin Market Segmentation
    11.1    Global Human Insulin Market by Product
        11.1.1    Market Overview 
        11.1.2    Drugs
        11.1.3    Delivery Device
    11.2    Global Human Insulin Market by Type
        11.2.1    Market Overview
        11.2.2    Biosimilars
            11.2.2.1    Long Acting
            11.2.2.2    Rapid Acting
            11.2.2.3    Pre-Mixed
        11.2.3    Delivery Device
            11.2.3.1    Intermediate-Acting
            11.2.3.2    Short Acting
            11.2.3.3    Pre-Mixed
    11.3    Global Human Insulin Market by Brand
        11.3.1    Market Overview
        11.3.2    HI Analogs and Biosimilars
            11.3.2.1    NovoRapid/Novolog
            11.3.2.2    Lantus
            11.3.2.3    Humalog
            11.3.2.4    Other Brands
        11.3.3    HI Biologics
            11.3.3.1    Insuman
            11.3.3.2    Humulin
            11.3.3.3    Actrapid, Insulatard, and Mixtard
            11.3.3.4    Others Brands
    11.4    Global Human Insulin Market by Delivery Device
        11.4.1    Market Overview
        11.4.2    Pens
            11.4.2.1    Disposable Pens
            11.4.2.2    Reusable Pens
        11.4.3    Syringes
        11.4.4    Pen Needles
            11.4.4.1    Standard Pen Needles
            11.4.4.2    Safety Pen Needles
        11.4.5    Others
    11.5    Global Human Insulin Market by Application
        11.5.1    Market Overview
            11.5.1.1    Type I Diabetes
            11.5.1.2    Type II Diabetes
    11.6    Global Human Insulin Market by Distribution Channel
        11.6.1    Market Overview
            11.6.1.1    Hospital Pharmacy
            11.6.1.2    Retail Pharmacy
            11.6.1.3    Others
    11.7    Global Human Insulin Market by Region
        11.7.1    Market Overview
        11.7.2    North America 
        11.7.3    Europe
        11.7.4    Asia Pacific
        11.7.5    Latin America
        11.7.6    Middle East and Africa
12    North America Human Insulin Market
    12.1    Market Share by Country
    12.2    United States of America
    12.3    Canada
13    Europe Human Insulin Market
    13.1    Market Share by Country
    13.2    United Kingdom
    13.3    Germany
    13.4    France
    13.5    Italy
    13.6    Others
14    Asia Pacific Human Insulin Market
    14.1    Market Share by Country
    14.2    China
    14.3    Japan
    14.4    India
    14.5    ASEAN
    14.6    Australia
    14.7    Others
15    Latin America Human Insulin Market
    15.1    Market Share by Country
    15.2    Brazil
    15.3    Argentina
    15.4    Mexico
    15.5    Others
16    Middle East and Africa Human Insulin Market
    16.1    Market Share by Country
    16.2    Saudi Arabia
    16.3    United Arab Emirates
    16.4    Nigeria
    16.5    South Africa
    16.6    Others
17    Patent Analysis
    17.1    Analysis by Type of Patent
    17.2    Analysis by Publication year
    17.3    Analysis by Issuing Authority
    17.4    Analysis by Patent Age
    17.5    Analysis by CPC Analysis
    17.6    Analysis by Patent Valuation 
    17.7    Analysis by Key Players
18    Grants Analysis
    18.1    Analysis by year
    18.2    Analysis by Amount Awarded
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Grant Application
    18.5    Analysis by Funding Institute
    18.6    Analysis by NIH Departments
    18.7    Analysis by Recipient Organization
19    Clinical Trials Analysis
    19.1     Analysis by Trial Registration Year 
    19.2    Analysis by Trial Status 
    19.3    Analysis by Trial Phase 
    19.4    Analysis by Therapeutic Area 
    19.5    Analysis by Geography  
20    Funding Analysis
    20.1    Analysis by Funding Instances
    20.2    Analysis by Type of Funding
    20.3    Analysis by Funding Amount
    20.4    Analysis by Leading Players
    20.5    Analysis by Leading Investors
    20.6    Analysis by Geography
21    Partnership and Collaborations Analysis
    21.1    Analysis by Partnership Instances
    21.2    Analysis by Type of Partnership
    21.3    Analysis by Leading Players
    21.4    Analysis by Geography
22    Regulatory Framework
    22.1    Regulatory Overview
        22.1.1    US FDA
        22.1.2    EU EMA
        22.1.3    INDIA CDSCO
        22.1.4    JAPAN PMDA
        22.1.5    Others
23    Supplier Landscape
    23.1    Nova Nordisk A/S
        23.1.1    Financial Analysis
        23.1.2    Product Portfolio
        23.1.3    Demographic Reach and Achievements
        23.1.4    Mergers and Acquisitions
        23.1.5    Certifications
    23.2    Biocon Limited
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Mergers and Acquisitions
        23.2.5    Certifications
    23.3    Sanofi S.A.
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Mergers and Acquisitions
        23.3.5    Certifications
    23.4    Pfizer Inc.
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Mergers and Acquisitions
        23.4.5    Certifications
    23.5    Eli Lilly and Company
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Mergers and Acquisitions
        23.5.5    Certifications
    23.6    Boehringer Ingelheim International GmbH
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Mergers and Acquisitions
        23.6.5    Certifications
    23.7    Tonghua Dongbao Pharmaceutical Co. Ltd.
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Mergers and Acquisitions
        23.7.5    Certifications
    23.8    Wockhardt
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Mergers and Acquisitions
        23.8.5    Certifications
    23.9    Julphar (Gulf Pharmaceutical Industries)
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Mergers and Acquisitions
        23.9.5    Certifications
    23.10    The United Laboratories International Holdings Limited
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Mergers and Acquisitions
        23.10.5    Certifications
    23.11    Ypsomed AG
        23.11.1    Financial Analysis
        23.11.2    Product Portfolio
        23.11.3    Demographic Reach and Achievements
        23.11.4    Mergers and Acquisitions
        23.11.5    Certifications
    23.12    Biodel Inc.
        23.12.1    Financial Analysis
        23.12.2    Product Portfolio
        23.12.3    Demographic Reach and Achievements
        23.12.4    Mergers and Acquisitions
        23.12.5    Certifications
24    Global Human Insulin Market- Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Company Competitiveness Analysis (Additional Insight)

    26.1    Very Small Companies
    26.2    Small Companies
    26.3    Mid-Sized Companies
    26.4    Large Companies
    26.5    Very Large Companies
27    Payment Methods (Additional Insight)
    27.1    Government Funded
    27.2    Private Insurance
    27.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

Human insulin was valued at USD 20.89 million in 2023.

The market is expected to grow at a CAGR of 3.4% from 2024 to 2032 to reach USD a value of USD 28.22 billion by 2032.

The industry is primarily being driven by the growing incidences of health issues such as obesity, changing consumer lifestyles, increased investments in research and development of advanced insulin injection mechanisms, and the availability of safety pen devices and pen needles for optimal insulin delivery.

The key trends boosting the market growth are the rising incidences of diabetes and the increasing geriatric population.

The major regions in the industry are North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.

The significant product types include drugs and delivery device.

The major types of the product include insulin analogs and biosimilars, and delivery device.

The significant brands include NovoRapid/Novolog, Humalog, Insuman, Humulin, Lantus, Actrapid, Insulatard, and Mixtard, and others.

The different delivery devices include pens, syringes, pen needles, and others.

The major applications of the product include Type 1 and Type 2.

The major players in the industry are Novo Nordisk A/S, Biocon Limited, Sanofi S.A., Pfizer Inc., Eli Lilly and Company, and others.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER